Thinking through
the work.

19 articles

• 3 August 2026Medicines systemsAfter Publication

  When three medicines numbers can all be right

  Before you choose the number that supports a decision, make the population, price basis, time window and source visible.

• 3 August 2026Founder perspectivesAfter Publication

  What feasibility support should actually buy

  Support matters when it converts expensive uncertainty into a clearer product, technical, commercial or stop decision.

• 3 August 2026Science and infrastructureAfter Publication

  What feasibility research must prove

  Feasibility becomes useful when the question, constraints, evidence threshold and stop or continue decision are explicit before the work begins.

• 3 August 2026Founder perspectivesAfter Publication

  The 30p rule: how discipline builds trust

  The smallest amount can reveal whether a business understands its margins, respects its records and keeps the promises hidden inside the numbers.

• 3 August 2026Medicines systemsAfter Publication

  From invention to adoption: the work between

  Invention creates a possibility. Adoption requires authority, evidence, implementation, review and a reason for people to change what they do.

• 3 August 2026Founder perspectivesAfter Publication

  From hyperfocus to governed execution

  If your mind sees the whole system at once, the next challenge is making that insight legible, owned and repeatable for everyone who must act on it.

• 3 August 2026Medicines systemsAfter Publication

  After NICE: making medicines access operational

  A recommendation can clarify what should be available. You still need an accountable route from evidence to a local decision, delivery and review.

• 3 August 2026Medicines systemsAfter Publication

  A trade deal is not a patient pathway

  A trade agreement can change the commercial and policy context. The value depends on whether each implementation gate has evidence, ownership and a route to learning.

• 2 August 2026Industry and licensing

  Luxury beauty licensing: who owns the brand, formula, factory and risk?

  Who owns the brand, formulation, manufacturing and regulatory responsibilities behind a luxury beauty licence.

• 1 August 2026Science and infrastructure

  Why formulation and analytical science should shape medicines infrastructure

  How formulation, analytical understanding and quality risk management should inform the environments medicine needs.

• 1 August 2026Science and infrastructure

  Why Glasgow City Region is being evaluated for a proposed medicines campus

  Why the AMIDS and Glasgow Airport corridor is being examined, and which questions a future location decision must answer.

• 1 August 2026Science and infrastructure

  What makes a science campus credible?

  The people, specialist capability and operating responsibilities that give a science campus a useful purpose.

• 1 August 2026Science and infrastructure

  From medicines intelligence to campus development

  Varun Sharma explains how medicines intelligence, formulation, development and future manufacturing can inform one founder thesis while each company, concept and capability retains its true operating status.

• 1 August 2026Science and infrastructure

  Designing responsible AI and robotics for future medicines operations

  Where responsible automation can support medicines work, with a defined task, human authority and evidence of performance.

• 21 March 2026Medicines systems

  Best-value biological medicines are the clearest near-term medicines productivity play in the NHS

  If NHS leaders are looking for a near-term medicines productivity play with a strong policy tailwind, best-value biological medicines should be near the top of the list.

• 20 March 2026Medicines systems

  NHS digital programmes do not fail on dashboards. They fail on deployment

  The NHS does not lack medicines dashboards. It lacks enough tools that turn those signals into action. That distinction matters because many digital programmes in medicines still behave as though visibility is the scarce resource.

• 19 March 2026Medicines systems

  The quarterly medicines leakage report every ICB should want in 2026/27

  If strategic commissioning is going to mean anything in 2026/27, it has to change how integrated care boards manage medicines value.

• 19 March 2026Medicines systems

  The NHS has not finished the generic job

  A familiar line turns up whenever medicines productivity is discussed in the NHS: generic prescribing has already been done. The easy gains have gone. We need to look elsewhere.

• 18 March 2026Medicines systems

  From pilot theatre to financial grip: how NHS CFOs should evaluate AI in medicines optimisation

  NHS finance leaders do not need another AI pitch. They need a disciplined way to decide whether a technology can release value within the financial rules they are already being held to.